TRK fusions have been identified in a wide range of cancers. They are present in a significant percentage of certain rare tumors, such as secretory breast carcinoma and infantile fibrosarcoma. However, they can also be found in more common cancers, albeit at a lower frequency, including lung cancer, thyroid cancer, and colorectal cancer. The occurrence of these fusions across diverse cancer types underscores their importance as a universal biomarker for targeted therapy.
